BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is surging on news that a drug met its primary endpoint and that it will seek approval in early 2013. The company’s Phase III study of GALNS is for the treatment of MPS IVA, a rare genetic disorder that is really called Mucopolysaccharidosis Type IVA.
The company now plans to submit its marketing applications in the first quarter of 2013. The endpoint target was a change in six-minute walk distance compared with placebo at 24 weeks in subjects receiving weekly infusions of GALNS. The study was said to be a randomized, double-blind, placebo-controlled study, and it evaluated two doses of GALNS for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVa.
Biomarin showed that patients dosed with GALNS at 2 mg/kg every other week did not show a meaningful or statistically significant change when evaluating the baseline compared to the placebo.
Shares are surging by more than 28% to $48.20, and this will mark a new 52-week high as the prior range was $30.06 to $44.18.
We would caution on one thing here. While MPS IVA is one of about 40 types of related genetic disorders, the overall population for this drug target is very small. BioMarin said:
The rate of incidence of MPS IVA is as yet unconfirmed and varies among different populations but estimates vary between 1 in 200,000 live births and 1 in 250,000 live births. The estimated prevalence is between 1,000 and 1,500 patients in the U.S., EU and Japan and between 1,500 to 2,000 patients in the rest of the world for a total of 2,500 to 3,000 patients.
That may be too small a market to add significantly to a company that already was worth $4.6 billion before this pop on the news.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
